FDA Seeks Specificity Over Sensitivity To ID Potentially Proarrhythmic Drugs
Executive Summary
The agency is looking at preclinical measurement of a drug’s effect on multiple ion channels, in silico modeling and stem cell assays as a possible alternative to “thorough” QT tests to assess the therapy’s impact on heart rhythm.
You may also be interested in...
FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes
A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.
QT Prolongation Trial For All Drugs Recommended By ICH Draft Guidance
All drugs should undergo a single cardiac QT interval prolongation trial early in development, an International Conference on Harmonization draft guidance on clinical evaluation of QT prolongation, released Sept. 13, states
Pre-Clinical QT Prolongation Guidance Urges In Vitro, In Vivo Studies
FDA's 1draft guidance on preclinical evaluation of QT prolongation urges drug companies to initiate follow-up studies when nonclinical studies are inconsistent